Introduction
Platelet inhibition represents the cornerstone of events. The aim of this article is to review current evidence and trends in coronary dual antiplatelet therapy (DAPT), such as preloading in patients with an acute coronary syndrome, optimal duration of DAPT after stent implantation and indications for long-term treatment, to provide an overview on the role of DAPT following percutaneous valve and structural interventions, and an update on the most recent information concerning the concomitant use of DAPT and oral anticoagulation. A short glance into future perspectives and trends in DAPT will be given.
Key words: dual antiplatelet therapy; pretreatment; clopidogrel; prasugrel; ticagrelor Even though much is known about the efficacy and safety of DAPT, as reflected by the most recent international guidelines [1] [2] [3] , some specific issues are a matter of ongoing discussion. The aim of this review is to give a concise overview of current knowledge on this topic and to discuss some open issues, such as preloading in patients with an acute coronary syndrome (ACS), which aims to prepare the lesion in view of the imminent percutaneous treatment, the optimal duration of DAPT after stent implantation, defined at the shortest period necessary to protect the stent against the risk of early and late stent thrombosis, and, finally, the longterm treatment (more than 12 months) recently considered as a potential alternative in patients at very high ischaemic risk ( fig. 2) . A final glimpse of new concepts, upcoming studies and applications of DAPT after valve and structural interventions, as well as in combination with oral anticoagulation, will also be provided.
Historical background
The hypothesis of an auxiliary effect of clopidogrel on top of aspirin in reducing cardiovascular ischaemic events rose from the well-established knowledge that platelet adhesion and activation occur through many different molecular mechanisms [4, 5] . After the introduction of bare metal stents (BMSs) in the early 1990s, aspirin was combined with an additional antithrombotic drug, initially ticlopidine, later clopidogrel, to prevent stent thrombosis during the first 4 weeks after stent implantation [6] . A few years later (2005) (2006) 
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Current role of dual antiplatelet therapy
In the following section we will focus on open issues about DAPT: the role of preloading in acute coronary syndromes, the optimal length of treatment after PCI in stable coronary artery disease and ACS, and the role of extended DAPT after 12 months in selected patients.
Preloading in acute coronary syndromes
The rationale for P2Y12 receptor blocker administration before PCI in ACS arises from the observation that the risk of early thrombotic complications, such as re-infarction or acute stent thrombosis, is directly related to the level of platelet reactivity ( fig. 3 ).
Several issues have to be addressed when considering preloading. First, the drug should be administered in a timely manner, early enough to allow complete inhibition at the time of PCI. Secondly, the delay between drug administration and its pharmacological action is related not only to the pharmacokinetics of the molecule, but also to some patient-specific clinical conditions (e.g., STEMI vs NSTEMI, low cardiac output syndromes, etc.)
that may further delay absorption. Thirdly, the addition of a second antiplatelet agent on top of aspirin obviously increases the haemorrhagic risk, particularly in the subgroup of patients (5-10%) who might benefit from accelerated surgical revascularisation.
Given these premises, preloading with a P2Y12 inhibitor has been considered a rationally appealing approach, Level of platelet inhibition (in %) 
Non-ST-segment elevation-ACS
In contrast to STEMI, the therapeutic goal of an- A summary of the current recommendation is given in Regardless of different therapeutic options and guideline recommendations, the current trend is to shorten DAPT to the minimum period required according to patient and stent characteristics. So far, this approach has Reprinted with permission.
STEMI
Routine pre-hospital pretreatment cannot be recommended for patients with STEMI over the in-lab administration of the drug since the two strategies had similar outcomes.
It can be advisable to administer potent and rapidly acting antiplatelet agents (prasugrel or ticagrelor) in the emergency department (i.e., ambulance) once the diagnosis of STEMI is confirmed and the patient proceeds to primary PCI.
NSTEMI
It is advisable to administer a potent and rapidly acting antiplatelet agent (prasugrel or ticagrelor) once the coronary anatomy is known (and the patient proceeds to immediate PCI).
If prasugrel or ticagrelor are contraindicated, pretreatment with clopidogrel before coronary angiography may be advisable for patients with low bleeding risk and a high likelihood for immediate PCI, especially if radial access is planned. In patients at high bleeding risk, the predefined DAPT period can be further shortened to 4 weeks when polymer-free drug-eluting stents are used. This is supported by evidence derived from the recent LEADERS FREE trial, which showed similar safety and superior efficacy with these stents as compared with conventional BMSs [29] .
Factors that need to be considered in estimating bleeding (favouring shorter DAPT) and ischaemic risk (favouring longer DAPT) are listed in table 4.
DAPT beyond 12 months
Several studies [14, 24, [30] [31] [32] [33] [34] hypothesised that prolonged platelet inhibition might result in a better protection against recurrent cardiovascular events.
The first study evaluating this strategy, the CHARISMA trial (with more than 15 000 patients at risk of, or with However, an increased risk of major bleeding for the two ticagrelor doses was also observed (2.6% for ticagrelor 90 mg vs 2.3% for ticagrelor 60 mg vs 1.0% for aspirin alone).
A summary of current evidence is available from an elegant meta-analysis, published in 2015 [35] , which clearly showed that DAPT maintained well beyond 12 months (up to 24-30 months) reduces the incidence of thrombotic complications, in particular stent thrombosis and myocardial infarction, at the price of an increase in major bleeding and possibly in all-cause mortality. In other words, the dichotomy between efficacy and safety still represents the Achille's heel of this appealing, but challenging approach.
In conclusion, although 2014 ESC guidelines on myocardial revascularisation do not recommend routine extension of DAPT, on the other hand and in the light of the more recent results of the DAPT and Pegasus tri- Table 4 : Characteristics related to increased ischaemic/ bleeding risk.
Increased ischaemic risk or risk of stent thrombosis (may favour longer-duration DAPT)
Recurrent ischaemic episode on DAPT ACS presentation in young patients 
Open questions and future perspectives
One of the future directions being currently investi- In other words, the antithrombotic perspective could considerably change in the coming years, according to the results of ongoing trials.
Platelet inhibition following structural interventions
The rationale behind platelet inhibition following 
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